Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

Science

Volumn 276, Issue 5314, 1997, Pages 960-964

  Cavert, Winston ^a   Notermans, Daan W ^b   Staskus, Katherine ^a   Wietgrefe, Stephen W ^a   Zupancic, Mary ^a   Gebhard, Kristin ^a   Henry, Keith ^a,c   Zhang, Zhi Qiang ^a   Mills, Roger ^d   McDade, Hugh ^e   Goudsmit, Jaap ^b   Danner, Sven A ^b   Haase, Ashley T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c REGIONS HOSPITAL   (United States)

^d ABBOTT LABORATORIES   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; KINETICS; LYMPHOID TISSUE; MONONUCLEAR CELL; PRIORITY JOURNAL; TONSIL;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DNA, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; KINETICS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TONSIL; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 15144342918     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.276.5314.960     Document Type: Article

References (26)

1. J. W. Mellors et al., Science 272, 1167 (1996); D. A. Katzenstein et al., N. Engl. J. Med. 335,1091 (1996); W. A. O'Brien et al., ibid. 334, 426 (1996).
2. J. W. Mellors et al., Science 272, 1167 (1996); D. A. Katzenstein et al., N. Engl. J. Med. 335,1091 (1996); W. A. O'Brien et al., ibid. 334, 426 (1996).
3. J. W. Mellors et al., Science 272, 1167 (1996); D. A. Katzenstein et al., N. Engl. J. Med. 335,1091 (1996); W. A. O'Brien et al., ibid. 334, 426 (1996).
4. A. T. Haase et al., Science 274, 985 (1996).
5. O. J. Cohen et at., J. Infect. Dis. 173, 849 (1996).
6. O. J. Cohen et al., Proc. Natl. Acad. Sci. U.S.A. 92, 6017 (1995).
7. A. Lafeuillade et al., J. Infect. Dis. 174, 404 (1996).
8. R. A. Faust et al., Otolaryngol. Head Neck Surg. 114, 593 (1996).
9. Protocol NUCB 2019. Participants underwent serial venipuncture for T cell subsets, plasma HIV RNA, and genotypic virology.
10. D.W. Notermans et al., in preparation.
11. X. Wei et al., Nature 373, 117 (1995); D. D. Ho et al., ibid., p. 123.
12. X. Wei et al., Nature 373, 117 (1995); D. D. Ho et al., ibid., p. 123.
13. A. S. Perelson et al., Science 271, 1582 (1996).
14. T. E. Mandel et al., Immunol. Rev. 53, 29 (1980).
15. S. L. Heath et al., Nature 377, 740 (1995).
16. + cell count was 194 cells per cubic millimeter.
17. 1/2 values, the mean pool sizes shown in Table 1, and the number of days of treatment. Because the FDC pool stores most virus produced, the simplest explanation for the earty rapid elimination of FDC-associated virus is that it is a result of treatment-induced reductions in MNC virus manufacture. Dividing the initial turnover per day in the FDC pool by the initial turnover per day of MNC thus gives an estimate of the number of copies of viral RNA per productively infected MNC.
18. J. M. Coffin, Science 267, 483 (1995).
19. M. Brahic and A. T. Haase, Curr. Top. Microbiol. Immunol. 143, 9 (1989).
20. 35S-labeled HIV RNA probe. After post-hybridization washes, nonspecific binding of antibodies was blocked by immersing the sections in 5% nonfat milk in phosphate-buffered saline (PBS) for 30 min. Sections were then treated with a 1:300 dilution of CD68 mAb (Dako, Carpinteria, CA) at 4°C overnight. After washing, slides were developed with a peroxidase-conjugated secondary antibody and diaminobenzidene substrate according the manufacturer's protocol (ABC Elite kit; Vector Labs, Burlingame, CA). The sections were then washed in PBS and 0.1 × PBS, dehydrated in ethanol containing 0.3 M ammonium acetate, and coated with nuclear track emulsion. After development, the slides were briefly counterstained in hematoxylin.
21. 4 copies per gram of LT.
22. 32P]deoxyadenosine triphosphate specific for sequences internal to the nesting primers (30-nucteotide oligomers: 5′-CATGGGTAAAAGTAGTAGAAGAGAAGGCTT-3′, 5′-GGGACATCAAGCAGCCATGCAAATGTTAAA-3′,5′- CCAAGGGGAAGTGACATAGCAGGAACTACT-3′).
23. J. Embretson et al., Nature 362, 359 (1993).
24. + T lymphocytes (Z.-Q. Zhang et al., in preparation).
25. A. T. Haase, in In Situ Hybridization: Applications to Neumbiology, K. L. Valentino, J. H. Eberwine, J. D. Barchas, Eds. (Oxford Univ. Press, New York, 1987), pp. 197-219.
26. We thank P. Dailey for technical assistance; C. O'Neill, T. Leonard, and G. Sedgewick for assistance with preparation of the manuscript and figures; and J. Leonard and G. Goodwin for clinical support. Supported by NIH grants Al 25017 and Al 28246.